Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma

Satoru Sagae, Nobuyuki Susumu, Akila N. Viswanathan, Daisuke Aoki, Floor J. Backes, Diane M. Provencher, Michelle Vaughan, Carien L. Creutzberg, Christian Kurzeder, Gunnar Kristensen, Chulmin Lee, Jean Emmanuel Kurtz, Rosalind M. Glasspool, William Small

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

OBJECTIVES: Uterine serous carcinoma (USC) represents a rare and aggressive histologic subtype of endometrial cancer, associated with a poor prognosis. This article critically reviews the literature pertinent to the epidemiology, pathology, molecular biology, diagnosis, management, and perspectives of patients with USC.

METHODS: As one of a series of The Gynecologic Cancer InterGroup (GCIG) Rare Tumor Working Group in London, November 2013, we discussed about USC many times with various experts among international GCIG groups.

RESULTS: Both USC and approximately 25% of high-grade endometrioid tumors represent extensive copy number alterations, few DNA methylation changes, low estrogen and progesterone levels, and frequent P53 mutations. Uterine serous carcinoma shares molecular characteristics with ovarian serous and basal-like breast carcinomas. In addition to optimal surgery, platinum- and taxane-based chemotherapy should be considered in the treatment of both early- and advanced-stage disease. The combination of radiation and chemotherapy appears to be associated with the highest survival rates. The role of radiation therapy in the management of this disease, with a high propensity for distant failures, remains elusive.

CONCLUSIONS: Uterine serous carcinoma is a unique and biologically aggressive subtype of endometrial cancer and should be studied as a distinct entity. Futures studies should identify the optimized chemotherapy and radiation regimens, sequence of therapy and schedule, and the role of targeted biologic therapy.

Original languageEnglish
Pages (from-to)S83-S89
JournalInternational Journal of Gynecological Cancer
Volume24
Issue number9
DOIs
Publication statusPublished - 2014 Nov 1

Fingerprint

Carcinoma
Neoplasms
Endometrial Neoplasms
Radiation
Drug Therapy
Biological Therapy
DNA Methylation
Disease Management
Combination Drug Therapy
Platinum
Progesterone
Molecular Biology
Appointments and Schedules
Estrogens
Epidemiology
Radiotherapy
Survival Rate
Pathology
Breast Neoplasms
Mutation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma. / Sagae, Satoru; Susumu, Nobuyuki; Viswanathan, Akila N.; Aoki, Daisuke; Backes, Floor J.; Provencher, Diane M.; Vaughan, Michelle; Creutzberg, Carien L.; Kurzeder, Christian; Kristensen, Gunnar; Lee, Chulmin; Kurtz, Jean Emmanuel; Glasspool, Rosalind M.; Small, William.

In: International Journal of Gynecological Cancer, Vol. 24, No. 9, 01.11.2014, p. S83-S89.

Research output: Contribution to journalArticle

Sagae, S, Susumu, N, Viswanathan, AN, Aoki, D, Backes, FJ, Provencher, DM, Vaughan, M, Creutzberg, CL, Kurzeder, C, Kristensen, G, Lee, C, Kurtz, JE, Glasspool, RM & Small, W 2014, 'Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma', International Journal of Gynecological Cancer, vol. 24, no. 9, pp. S83-S89. https://doi.org/10.1097/IGC.0000000000000264
Sagae, Satoru ; Susumu, Nobuyuki ; Viswanathan, Akila N. ; Aoki, Daisuke ; Backes, Floor J. ; Provencher, Diane M. ; Vaughan, Michelle ; Creutzberg, Carien L. ; Kurzeder, Christian ; Kristensen, Gunnar ; Lee, Chulmin ; Kurtz, Jean Emmanuel ; Glasspool, Rosalind M. ; Small, William. / Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma. In: International Journal of Gynecological Cancer. 2014 ; Vol. 24, No. 9. pp. S83-S89.
@article{3b18f8b971b74fc5b0170be053cd2bc6,
title = "Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma",
abstract = "OBJECTIVES: Uterine serous carcinoma (USC) represents a rare and aggressive histologic subtype of endometrial cancer, associated with a poor prognosis. This article critically reviews the literature pertinent to the epidemiology, pathology, molecular biology, diagnosis, management, and perspectives of patients with USC.METHODS: As one of a series of The Gynecologic Cancer InterGroup (GCIG) Rare Tumor Working Group in London, November 2013, we discussed about USC many times with various experts among international GCIG groups.RESULTS: Both USC and approximately 25{\%} of high-grade endometrioid tumors represent extensive copy number alterations, few DNA methylation changes, low estrogen and progesterone levels, and frequent P53 mutations. Uterine serous carcinoma shares molecular characteristics with ovarian serous and basal-like breast carcinomas. In addition to optimal surgery, platinum- and taxane-based chemotherapy should be considered in the treatment of both early- and advanced-stage disease. The combination of radiation and chemotherapy appears to be associated with the highest survival rates. The role of radiation therapy in the management of this disease, with a high propensity for distant failures, remains elusive.CONCLUSIONS: Uterine serous carcinoma is a unique and biologically aggressive subtype of endometrial cancer and should be studied as a distinct entity. Futures studies should identify the optimized chemotherapy and radiation regimens, sequence of therapy and schedule, and the role of targeted biologic therapy.",
author = "Satoru Sagae and Nobuyuki Susumu and Viswanathan, {Akila N.} and Daisuke Aoki and Backes, {Floor J.} and Provencher, {Diane M.} and Michelle Vaughan and Creutzberg, {Carien L.} and Christian Kurzeder and Gunnar Kristensen and Chulmin Lee and Kurtz, {Jean Emmanuel} and Glasspool, {Rosalind M.} and William Small",
year = "2014",
month = "11",
day = "1",
doi = "10.1097/IGC.0000000000000264",
language = "English",
volume = "24",
pages = "S83--S89",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma

AU - Sagae, Satoru

AU - Susumu, Nobuyuki

AU - Viswanathan, Akila N.

AU - Aoki, Daisuke

AU - Backes, Floor J.

AU - Provencher, Diane M.

AU - Vaughan, Michelle

AU - Creutzberg, Carien L.

AU - Kurzeder, Christian

AU - Kristensen, Gunnar

AU - Lee, Chulmin

AU - Kurtz, Jean Emmanuel

AU - Glasspool, Rosalind M.

AU - Small, William

PY - 2014/11/1

Y1 - 2014/11/1

N2 - OBJECTIVES: Uterine serous carcinoma (USC) represents a rare and aggressive histologic subtype of endometrial cancer, associated with a poor prognosis. This article critically reviews the literature pertinent to the epidemiology, pathology, molecular biology, diagnosis, management, and perspectives of patients with USC.METHODS: As one of a series of The Gynecologic Cancer InterGroup (GCIG) Rare Tumor Working Group in London, November 2013, we discussed about USC many times with various experts among international GCIG groups.RESULTS: Both USC and approximately 25% of high-grade endometrioid tumors represent extensive copy number alterations, few DNA methylation changes, low estrogen and progesterone levels, and frequent P53 mutations. Uterine serous carcinoma shares molecular characteristics with ovarian serous and basal-like breast carcinomas. In addition to optimal surgery, platinum- and taxane-based chemotherapy should be considered in the treatment of both early- and advanced-stage disease. The combination of radiation and chemotherapy appears to be associated with the highest survival rates. The role of radiation therapy in the management of this disease, with a high propensity for distant failures, remains elusive.CONCLUSIONS: Uterine serous carcinoma is a unique and biologically aggressive subtype of endometrial cancer and should be studied as a distinct entity. Futures studies should identify the optimized chemotherapy and radiation regimens, sequence of therapy and schedule, and the role of targeted biologic therapy.

AB - OBJECTIVES: Uterine serous carcinoma (USC) represents a rare and aggressive histologic subtype of endometrial cancer, associated with a poor prognosis. This article critically reviews the literature pertinent to the epidemiology, pathology, molecular biology, diagnosis, management, and perspectives of patients with USC.METHODS: As one of a series of The Gynecologic Cancer InterGroup (GCIG) Rare Tumor Working Group in London, November 2013, we discussed about USC many times with various experts among international GCIG groups.RESULTS: Both USC and approximately 25% of high-grade endometrioid tumors represent extensive copy number alterations, few DNA methylation changes, low estrogen and progesterone levels, and frequent P53 mutations. Uterine serous carcinoma shares molecular characteristics with ovarian serous and basal-like breast carcinomas. In addition to optimal surgery, platinum- and taxane-based chemotherapy should be considered in the treatment of both early- and advanced-stage disease. The combination of radiation and chemotherapy appears to be associated with the highest survival rates. The role of radiation therapy in the management of this disease, with a high propensity for distant failures, remains elusive.CONCLUSIONS: Uterine serous carcinoma is a unique and biologically aggressive subtype of endometrial cancer and should be studied as a distinct entity. Futures studies should identify the optimized chemotherapy and radiation regimens, sequence of therapy and schedule, and the role of targeted biologic therapy.

UR - http://www.scopus.com/inward/record.url?scp=84936082191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936082191&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000000264

DO - 10.1097/IGC.0000000000000264

M3 - Article

C2 - 25341586

AN - SCOPUS:84936082191

VL - 24

SP - S83-S89

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 9

ER -